Pulse Biosciences (NASDAQ:PLSE) Shares Gap Up on Insider Buying Activity

Pulse Biosciences, Inc. (NASDAQ:PLSE) shares gapped up before the market opened on Monday after an insider bought additional shares in the company. The stock had previously closed at $17.65, but opened at $18.51. Pulse Biosciences shares last traded at $19.25, with a volume of 35,220 shares changing hands.

Specifically, Director Robert W. Duggan acquired 56,054 shares of the stock in a transaction dated Wednesday, December 11th. The shares were purchased at an average price of $17.35 per share, for a total transaction of $972,536.90. Following the transaction, the director now owns 42,228,057 shares in the company, valued at $732,656,788.95. This represents a 0.13 % increase in their position. The acquisition was disclosed in a document filed with the SEC, which is available through the SEC website.

Wall Street Analysts Forecast Growth

Separately, StockNews.com upgraded shares of Pulse Biosciences to a “sell” rating in a research report on Thursday, December 12th.

Pulse Biosciences Trading Up 8.6 %

The company’s 50-day moving average price is $17.74 and its two-hundred day moving average price is $16.50.

Pulse Biosciences (NASDAQ:PLSE) last posted its quarterly earnings data on Wednesday, October 30th. The company reported ($0.21) earnings per share for the quarter. During the same quarter in the previous year, the firm posted ($0.19) EPS.

Hedge Funds Weigh In On Pulse Biosciences

Several institutional investors and hedge funds have recently made changes to their positions in PLSE. Price T Rowe Associates Inc. MD bought a new position in shares of Pulse Biosciences during the 1st quarter valued at $88,000. Quest Partners LLC bought a new position in shares of Pulse Biosciences during the 2nd quarter valued at $91,000. Cetera Advisors LLC bought a new position in shares of Pulse Biosciences during the 1st quarter valued at $109,000. Rhumbline Advisers grew its holdings in shares of Pulse Biosciences by 6.7% during the 2nd quarter. Rhumbline Advisers now owns 25,729 shares of the company’s stock valued at $288,000 after purchasing an additional 1,608 shares during the last quarter. Finally, Franklin Resources Inc. bought a new position in shares of Pulse Biosciences during the 3rd quarter valued at $378,000. Institutional investors own 76.95% of the company’s stock.

About Pulse Biosciences

Pulse Biosciences, Inc operates as a novel bioelectric medicine company. The company offers CellFX System, a tunable, software-enabled, and console-based platform that delivers nano second duration pulses of electrical energy to non-thermally clear targeted cells while sparing adjacent non-cellular tissue to treat a various medical condition by using its Nano-Pulse Stimulation technology.